By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories has completed its offer to exchange up to $300 million aggregate principal amount of its 8 percent Senior Subordinated Notes due 2016 for any and all of its outstanding 8 percent Senior Subordinated Notes due 2016 that were issued in a private placement. All of the notes were tendered before the deadline yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.